A Safe, Fibrosis-Mitigating, and Scalable Encapsulation Device Supports Long-Term Function of Insulin-Producing Cells.

Autor: Liu W; Department of Biological and Environmental Engineering, Cornell University, Ithaca, NY, 14853, USA.; Key Laboratory of Textile Science & Technology, Ministry of Education, College of Textiles, Donghua University, Shanghai, 201620, China., Flanders JA; Department of Clinical Sciences, Cornell University, Ithaca, NY, 14853, USA., Wang LH; Department of Biological and Environmental Engineering, Cornell University, Ithaca, NY, 14853, USA., Liu Q; Department of Biological and Environmental Engineering, Cornell University, Ithaca, NY, 14853, USA., Bowers DT; Department of Biological and Environmental Engineering, Cornell University, Ithaca, NY, 14853, USA., Wang K; Department of Cardiac Surgery, Boston Children's Hospital, Boston, MA, 02115, USA.; Department of Surgery, Harvard Medical School, Boston, MA, 02115, USA., Chiu A; Department of Biological and Environmental Engineering, Cornell University, Ithaca, NY, 14853, USA., Wang X; Department of Biological and Environmental Engineering, Cornell University, Ithaca, NY, 14853, USA., Ernst AU; Department of Biological and Environmental Engineering, Cornell University, Ithaca, NY, 14853, USA., Shariati K; Department of Biological and Environmental Engineering, Cornell University, Ithaca, NY, 14853, USA., Caserto JS; Department of Biological and Environmental Engineering, Cornell University, Ithaca, NY, 14853, USA.; Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, 14853, USA., Parker B; Department of Biological and Environmental Engineering, Cornell University, Ithaca, NY, 14853, USA., Gao D; Department of Biological and Environmental Engineering, Cornell University, Ithaca, NY, 14853, USA., Plesser MD; Department of Biological and Environmental Engineering, Cornell University, Ithaca, NY, 14853, USA., Grunnet LG; Stem Cell Delivery and Pharmacology, Novo Nordisk A/S, Måløv, 2760, Denmark., Rescan C; Stem Cell Delivery and Pharmacology, Novo Nordisk A/S, Måløv, 2760, Denmark., Pimentel Carletto R; Stem Cell Delivery and Pharmacology, Novo Nordisk A/S, Måløv, 2760, Denmark., Winkel L; Stem Cell Delivery and Pharmacology, Novo Nordisk A/S, Måløv, 2760, Denmark., Melero-Martin JM; Department of Cardiac Surgery, Boston Children's Hospital, Boston, MA, 02115, USA.; Department of Surgery, Harvard Medical School, Boston, MA, 02115, USA.; Harvard Stem Cell Institute, Cambridge, MA, 02138, USA., Ma M; Department of Biological and Environmental Engineering, Cornell University, Ithaca, NY, 14853, USA.
Jazyk: angličtina
Zdroj: Small (Weinheim an der Bergstrasse, Germany) [Small] 2022 Feb; Vol. 18 (8), pp. e2104899. Date of Electronic Publication: 2021 Dec 13.
DOI: 10.1002/smll.202104899
Abstrakt: Encapsulation and transplantation of insulin-producing cells offer a promising curative treatment for type 1 diabetes (T1D) without immunosuppression. However, biomaterials used to encapsulate cells often elicit foreign body responses, leading to cellular overgrowth and deposition of fibrotic tissue, which in turn diminishes mass transfer to and from transplanted cells. Meanwhile, the encapsulation device must be safe, scalable, and ideally retrievable to meet clinical requirements. Here, a durable and safe nanofibrous device coated with a thin and uniform, fibrosis-mitigating, zwitterionically modified alginate hydrogel for encapsulation of islets and stem cell-derived beta (SC-β) cells is reported. The device with a configuration that has cells encapsulated within the cylindrical wall, allowing scale-up in both radial and longitudinal directions without sacrificing mass transfer, is designed. Due to its facile mass transfer and low level of fibrotic reactions, the device supports long-term cell engraftment, correcting diabetes in C57BL6/J mice with rat islets for up to 399 days and SCID-beige mice with human SC-β cells for up to 238 days. The scalability and retrievability in dogs are further demonstrated. These results suggest the potential of this new device for cell therapies to treat T1D and other diseases.
(© 2021 Wiley-VCH GmbH.)
Databáze: MEDLINE
Externí odkaz: